详情页 - 云南省第一人民医院机构库

当前位置：首页 > 详情页

Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.

112| 认领 | 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China [2]Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China [3]Department of Thoracic Surgery and Oncology, Harbin Medical University Cancer Hospital, Harbin, China [4]Thoracic Medicine Department II, Hunan Cancer Hospital, Changsha, China [5]Thoracic Surgery Department, Tongji Hospital, Tongji Medical College of HUST, Wuhan, China [6]Medical Oncology, Nantong Tumor Hospital, Nantong, China [7]Thoracic Surgery Department, Zhongshan Hospital, Fudan University, Shanghai, China [8]Oncology Department, Fuzhou Pulmonary Hospital of Fujian, Fuzhou, China [9]Thoracic Surgery Department, Zhejiang Cancer Hospital, Hangzhou, China [10]Thoracic Surgery Department, Jiangsu Cancer Hospital, Nanjing, China [11]Thoracic Surgery Department, Fujian Medical University Union Hospital, Fuzhou, China [12]Tumorchemotherapy Department, Anhui Provincial Hospital, Hefei, China [13]Thoracic Surgery Department, The First Hospital of Jilin University, Changchun, China [14]Thoracic Surgery Department,The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China [15]Respiratory Medicine Department,The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China [16]Thoracic Surgery Department, Affiliated Cancer Hospital and Institute of Guangzhou Medical University, Guangzhou, China [17]Department of Pulmonary Oncology, The 5th Medical Center of PLA General Hospital, Beijing, China [18]Thoracic Surgery Department II, Beijing Chest Hospital, Capital Medical University, Beijing, China [19]Thoracic Surgery Department, Shenzhen People’s Hospital, Shenzhen, China [20]Oncology Department, The First People’s Hospital of Changde City, Changde, China [21]Thoracic Surgery Department, The 6th Medical Center of PLA General Hospital, Beijing, China [22]Medical Oncology, Cancer Hospital of Shantou University Medical College, Shantou, China [23]Oncology Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China [24]Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, China [25]Thoracic Surgery Department, Chinese PLA General Hospital, Beijing, China [26]Thoracic Surgery Department, The First Affiliated Hospital of Soochow University, Suzhou, China [27]Thoracic Surgery Department I, Yunnan Cancer Hospital, Kunming, China [28]Cardio-Thoracic Surgery, The First People’s Hospital of Changzhou, Changzhou, China [29]Thoracic Surgery Department, First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China [30]Betta Pharmaceuticals, Hangzhou,China

出处：

DOI：

ISSN：

摘要：

Icotinib has provided survival benefits for patients with advanced, epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC). We aimed to compare icotinib with chemotherapy in patients with EGFR-mutant stage II-IIIA NSCLC after complete tumour resection. Here, we report the results from the preplanned interim analysis of the study.In this multicentre, randomised, open-label, phase 3 trial done at 29 hospitals in China, eligible patients were aged 18-70 years, had histopathogically confirmed stage II-IIIA NSCLC, had complete resection up to 8 weeks before random assignment, were treatment-naive, and had confirmed activation mutation in exon 19 or exon 21 of the EGFR gene. Participants were randomly assigned (1:1) with an interactive web-based response system to receive either oral icotinib 125 mg thrice daily for 2 years or four 21-day cycles of intravenous chemotherapy (vinorelbine 25 mg/m2 on days 1 and 8 of each cycle plus cisplatin 75 mg/m2 on day 1 of each cycle for adenocarcinoma or squamous carcinoma; or pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 on day 1 every 3 weeks for non-squamous carcinoma). The primary endpoint was disease-free survival assessed in the full analysis set. Secondary endpoints were overall survival assessed in the full analysis set and safety assessed in all participants who received study drug. This trial is registered with ClinicalTrials.gov, NCT02448797.Between June 8, 2015, and August 2, 2019, 322 patients were randomly assigned to icotinib (n=161) or chemotherapy (n=161); the full analysis set included 151 patients in the icotinib group and 132 in the chemotherapy group. Median follow-up in the full analysis set was 24·9 months (IQR 16·6-36·4). 40 (26%) of 151 patients in the icotinib group and 58 (44%) of 132 patients in the chemotherapy group had disease relapse or death. Median disease-free survival was 47·0 months (95% CI 36·4-not reached) in the icotinib group and 22·1 months (16·8-30·4) in the chemotherapy group (stratified hazard ratio [HR] 0·36 [95% CI 0·24-0·55]; p<0·0001). 3-year disease-free survival was 63·9% (95% CI 51·8-73·7) in the icotinib group and 32·5% (21·3-44·2) in the chemotherapy group. Overall survival data are immature with 14 (9%) deaths in the icotinib group and 14 (11%) deaths in the chemotherapy. The HR for overall survival was 0·91 (95% CI 0·42-1·94) in the full analysis set. Treatment-related serious adverse events occurred in two (1%) of 156 patients in the icotinib group and 19 (14%) of 139 patients in the chemotherapy group. No interstitial pneumonia or treatment-related death was observed in either group.Our results suggest that compared with chemotherapy, icotinib significantly improves disease-free survival and has a better tolerability profile in patients with EGFR-mutant stage II-IIIA NSCLC after complete tumour resection.Betta Pharmaceuticals TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.Copyright © 2021 Elsevier Ltd. All rights reserved.

基金：

语种：

高被引：

被引次数：

WOS：

PubmedID：

中科院(CAS)分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区危重病医学 1 区呼吸系统

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区危重病医学 1 区呼吸系统

JCR分区：

出版当年[2020]版：

Q1 RESPIRATORY SYSTEM Q1 CRITICAL CARE MEDICINE

最新[2023]版：

Q1 CRITICAL CARE MEDICINE Q1 RESPIRATORY SYSTEM

影响因子： 38.7 最新[2023版] 41.3 最新五年平均 30.7 出版当年[2020版] 29.048 出版当年五年平均 25.094 出版前一年[2019版] 102.642 出版后一年[2021版]

第一作者：

第一作者机构： [1]Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China [*2]Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China

共同第一作者：

通讯作者：

通讯机构： [1]Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China [2]Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China [*1]Department of Medical Oncology, Shanghai Pulmonary Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, 200433, China [*2]Department of Thoracic Surgery and Oncology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, 510120, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. $(function () { $("[data-toggle='tooltip']").tooltip(); });

文献详情

Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.